US20260335420
2026-10-29
Human necessities
A61K39/0225
The document discusses mRNA vaccines designed to prevent Lyme disease, caused by various Borrelia bacteria. These vaccines include mRNA sequences encoding proteins from Borrelia outer surface protein A (OspA), particularly focusing on multiple serotypes. The innovative approach involves using mRNA technology to encode these proteins, potentially offering a new method for Lyme disease prevention.
The vaccines consist of mRNA polynucleotides encoding Borrelia OspA proteins, which may include additional modifications like heterologous transmembrane domains. These modifications can originate from influenza virus proteins. The mRNA is delivered using lipid nanoparticles, enhancing stability and delivery efficiency.
A significant feature of the vaccine is its coverage of multiple Borrelia serotypes, addressing the diversity of Lyme disease-causing bacteria in different geographical regions. The vaccine can include up to seven different mRNA sequences, each encoding a unique OspA protein from various Borrelia species like B. burgdorferi, B. afzelii, B. garinii, and B. bavariensis.
The vaccines may incorporate specific amino acid modifications to the OspA proteins, such as changes to N glycosylation sites or specific mutations like Y165F, V166I, T170R, and L171F. These modifications aim to enhance immunogenicity and expression stability in mammalian cells, improving the vaccine's effectiveness.
By leveraging mRNA technology, these vaccines aim to fill the current gap in Lyme disease prevention, particularly in the United States where no vaccines are currently approved for human use. This approach could significantly reduce the incidence of Lyme disease, which is underreported and potentially affects a much larger population than current statistics indicate.